Securities code: 301080 securities abbreviation: Acrobiosystems Co.Ltd(301080) Announcement No.: 2022-001 Acrobiosystems Co.Ltd(301080)
Performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
Expected performance: □ loss □ turning loss into profit ■ rising in the same direction □ falling in the same direction
The current reporting period of the project is the same period of last year
Operating income: 382 million yuan – 402 million yuan operating income:
The operating income was 246.3186 million yuan, an increase of 55% – 63% over the same period of last year
Profit attributable to listed companies: 170 million yuan – 187 million yuan profit: 11588.26 net profit of shareholders increased by 47% – 61% over the same period of last year
Profit after deducting non recurring profit and loss: 163 million yuan – 180 million yuan profit: 11673.74 net profit increased by 40% – 54% over the same period of last year
2、 Communication with accounting firms
The performance forecast has not been audited by the accounting firm. The company has pre communicated with the annual audit accounting firm on the performance forecast. There is no disagreement between the company and the annual audit accounting firm on the performance forecast. 3、 Explanation of performance change reasons
1. The company seizes the rapid development opportunity of antibody drugs and cellular immunotherapy, focuses on and deeply cultivates the key biological reagent fields such as recombinant protein and antibody, and forms a strong competitive advantage in product brand, product quality, product type, large-scale production capacity, R & D and technical service capacity, supply chain management capacity, etc. In 2021, the sales of the company’s core products continued to rise, which led to a significant increase in the scale of operating revenue and profitability. The company expects that the operating revenue in 2021 will be 382-402 million yuan, a year-on-year increase of 55% – 63%.
2. The company expects that the revenue of non covid-19 virus epidemic prevention related products in 2021 will be 295 million yuan – 305 million yuan, with a year-on-year increase of 70% – 76%. In terms of R & D, in 2021, the company will increase R & D efforts to continuously improve the product system following research hotspots in order to meet the latest needs of the market and customers; In terms of product quality, the company strictly controls product quality and provides customers with more professional product application support. Through the improvement of scientific research ability and product quality, the company’s market competitiveness has been continuously enhanced, and the non covid-19 related income has continued to grow at a high speed.
3. The company expects that the sales revenue of covid-19 virus epidemic prevention related products will be 87-97 million yuan in 2021, with a year-on-year increase of 20% – 33%. In 2021, the company accelerated the response speed to covid-19 virus mutant strain, and developed high-standard and high-quality antibodies, antigens, kits and other products in a short time for global scientific research and industrial customers to help fight the epidemic research.
4、 Other relevant instructions
1. This performance forecast is the preliminary calculation result of the company’s financial department and has not been audited by the audit institution.
2. The specific data of the company’s 2021 annual performance will be disclosed in detail in the company’s 2021 annual report. Please make careful decisions and pay attention to investment risks.
5、 Documents for future reference
Description of the board of directors on the performance forecast of 2021.
It is hereby announced.
Acrobiosystems Co.Ltd(301080) board of directors January 21, 2022
